Our news section contains recent news on neuroendocrine tumors, upcoming NANETS events and information, and people in our community. Have a suggestion? Please click here to contact us.

NET Funding Opportunity: Neuroendocrine Tumor Specialized Program of Research Excellence (SPORE)

NANETS member M. Sue O’Dorisio, MD, PhD, of the University of Iowa Hospitals & Clinics, seeks applicants for two Developmental Research Program awards ($50,000 each) and one Career Enhancement Program award ($100,000). The deadline to apply is Monday, July 17, 2017.

NANETS Announces Symposium Keynote

Drew Pardoll, MD, PhD, of Johns Hopkins Medical Institutions, will be presenting the keynote on Friday, October 20 at the 2017 symposium in Philadelphia, Pennsylvania. His topic will be "Harnessing the Patient’s Immune System Against Their Tumor: The Revolution in Cancer Therapy." He observed that the application of 40 years of basic immunology and cancer immunology is now paying off in the establishment of immunotherapy as a new pillar of cancer treatment.

NANETS2017 Early Bird Registration - Open Now!

The North American Neuroendocrine Tumor Society (NANETS) invites you to attend our 10th Annual Symposium. Join us in Philadelphia, Pennsylvania, USA, on October 19-21, 2017 for the premier gathering of medical professionals involved in the study and treatment of neuroendocrine tumor (NET) disease.

Featured in Pancreas

Featured in the March 2017 issue of Pancreas are the NANETS 2016 symposium abstracts and an article on Complicated Case Presentation: Management of Pancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1. NANETS members are granted free online 

NANETS2017 Call for Abstracts - Open Now!

The North American Neuroendocrine Tumor Society (NANETS) welcomes abstracts for the 10th annual NANETS Symposium, which will be held in Philadelphia, Pennsylvania, USA, on October 19-21, 2017. The deadline for abstract submissions is Monday, June 26, 2017. One of the key goals of NANETS is to provide a platform for highlighting neuroendocrine tumor research.

NANETS Transition Update

It has been a little over a month since we established our new headquarters and staff in New York. I'm pleased to report it has been a productive transition which has allowed us to align our organization with many of our strategic goals.

The intent of this email and the attached .pdf is to provide you an update on some of the more important elements of our recent work. Have questions? Email me or the staff anytime at staff@nanets.net.

In memoriam Dirk J. Kwekkeboom (1958 - 2017)

Dirk J. KwekkeboomDirk J. Kwekkeboom, MD, widely regarded as one of Europe’s foremost experts on peptide receptor radiotherapy (PRRT), passed away March 8, 2017, at the age of 58. 

NANETS Welcomes New Management Team

In January, NANETS extended its thanks and gratitude to our outgoing executive director. This month, I share the news that NANETS has established a new office headquarters and staff.

It's been a productive month as leaders and committee chairs work to align new staff with the goals identified in our strategic plan. In making this transition, the Board of Directors has added capacity and created a foundation that will support growth and continue to advance our mission to improve neuroendocrine tumor (NET) disease management through increased research and educational opportunities.

FDA approves Xermelo for carcinoid syndrome diarrhea

The U.S. Food and Drug Administration today approved Xermelo (telotristat ethyl) tablets in combination with somatostatin analog (SSA) therapy for the treatment of adults with carcinoid syndrome diarrhea that SSA therapy alone has inadequately controlled. 

“Today’s approval will provide patients whose carcinoid syndrome diarrhea is not adequately controlled with another treatment option,” said Julie Beitz, M.D., director of the Office of Drug Evaluation III in the FDA’s Center for Drug Evaluation and Research.

Pages